Ischemic and bleeding outcomes after angiolite stent implantation and an abbreviated dual antiplatelet therapy. A 2x2 factorial, all-comer, multicenter, randomized controlled trial: ANGIODAPT

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507015-35-00

Enrollment

2312

Registered

2023-10-04

Start date

2023-10-06

Completion date

Unknown

Last updated

2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

Target lesion failure: cardiovascular death, target-vessel myocardial infarction, and target lesion revascularization (clinically driven) at 1-year follow-up., Adverse ischemic events: All-cause death, myocardial infarction, stroke, or urgent target vessel revascularization.

Detailed description

Ischemic event including all-cause death, non-fatal myocardial infarction, or stroke.

Interventions

DRUGCLOPIDOGREL

DRUGACETYLSALICYLIC ACID

DRUGTICAGRELOR

DRUGPRASUGREL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Target lesion failure: cardiovascular death, target-vessel myocardial infarction, and target lesion revascularization (clinically driven) at 1-year follow-up., Adverse ischemic events: All-cause death, myocardial infarction, stroke, or urgent target vessel revascularization.	—

Secondary

Measure	Time frame
Ischemic event including all-cause death, non-fatal myocardial infarction, or stroke.	—

Countries

Belgium, France, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026